Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: a potential neoadjuvant T-cell immunotherapy for triple negative breast cancer.
S. R. Burkholz, C. V. Herst, R. T. Carback, P. E. Harris, R. M. Rubsamen
This study evaluates a survivin peptide vaccine in a 4T1 murine model, showing slower tumor growth and a gamma IFN Elispot response in vaccinated mice.
bioRxiv · Jul 25, 2022 · PreprintImmunology